Phase II Study to evaluate the response on two blocks of topotecan and carboplatin

Phase II study for patients with chemosensible soft tissue sarcoma stage IV in children and adolescents ; response according to RECIST criteria following two blocks of combination therapy consisting of Topotecan and carboplatin

Inclusion Criteria:

• Soft tissue sarcoma chemosensible, stage IV
• age < 21
• measurable tumor lesions

Exclusion Criteria:

• Lack of cooperation by the patient
• no willingness of follow-up examinations
• participation on another clinical trial at the same time
• death due to the sickness within four weeks